Mesa Laboratories, Inc. (NASDAQ:MLAB) SVP Sells $187,375.00 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) SVP Brian David Archbold sold 1,499 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $125.00, for a total transaction of $187,375.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Mesa Laboratories Stock Down 2.0 %

Shares of NASDAQ MLAB traded down $2.46 during mid-day trading on Monday, hitting $123.25. 13,070 shares of the stock traded hands, compared to its average volume of 43,404. The company has a market cap of $666.78 million, a price-to-earnings ratio of -2.67 and a beta of 0.85. The stock has a fifty day moving average price of $118.18 and a 200-day moving average price of $109.18. Mesa Laboratories, Inc. has a 52 week low of $82.86 and a 52 week high of $141.17. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.37 and a current ratio of 1.94.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings data on Monday, August 5th. The medical instruments supplier reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.74 by $0.55. Mesa Laboratories had a negative net margin of 111.89% and a positive return on equity of 18.95%. The business had revenue of $58.17 million for the quarter, compared to analysts’ expectations of $55.90 million. Research analysts anticipate that Mesa Laboratories, Inc. will post 7.91 EPS for the current year.

Mesa Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 16th. Shareholders of record on Friday, August 30th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date is Friday, August 30th. Mesa Laboratories’s dividend payout ratio is -1.36%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MLAB shares. Evercore ISI upped their target price on shares of Mesa Laboratories from $106.00 to $120.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 6th. Wells Fargo & Company started coverage on shares of Mesa Laboratories in a research note on Tuesday, August 27th. They set an “underweight” rating and a $120.00 price target on the stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MLAB. Louisiana State Employees Retirement System raised its stake in Mesa Laboratories by 4.0% during the second quarter. Louisiana State Employees Retirement System now owns 2,600 shares of the medical instruments supplier’s stock valued at $226,000 after purchasing an additional 100 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Mesa Laboratories by 6.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,873 shares of the medical instruments supplier’s stock valued at $316,000 after purchasing an additional 175 shares during the last quarter. EntryPoint Capital LLC increased its position in shares of Mesa Laboratories by 35.2% during the 1st quarter. EntryPoint Capital LLC now owns 741 shares of the medical instruments supplier’s stock valued at $81,000 after purchasing an additional 193 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in Mesa Laboratories by 515.6% during the 4th quarter. Quadrant Capital Group LLC now owns 277 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 232 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in Mesa Laboratories in the second quarter worth $26,000. 90.60% of the stock is currently owned by institutional investors.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.